262 results
Page 5 of 14
424B3
rel00l0vsfaslynwer
11 Aug 21
Prospectus supplement
4:34pm
8-K
re3n09wo2dyaeg40
11 Aug 21
GeoVax Reports 2021 Second Quarter Financial Results
4:30pm
POS AM
rqg3iah1
24 Mar 21
Prospectus update (post-effective amendment)
9:17am
8-K
EX-99.1
3yba5som
23 Mar 21
GeoVax Reports 2020 Year-End Financial Results
4:35pm
D
us9 2ilwhpy3hx2mdgtu
25 Feb 21
$495K in equity / options, sold $495K, 1 investor
12:00am
8-K
EX-1.01
jr2x1 3r1gn
11 Feb 21
GeoVax Announces Pricing of $9.0 Million Bought Deal Offering
9:21am
424B5
io826
11 Feb 21
Prospectus supplement for primary offering
9:17am
8-K
m9k1sidrcyr 0ym
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
8-K
EX-10.1
26uqvcmqq
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
8-K
EX-99.1
jb5j u5z5fe
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
424B3
ekrjflvkvipjyr 2yp
5 Nov 20
Prospectus supplement
5:17pm
8-K
7d4f5f5g28vepb5w
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm
8-K
EX-99.1
1wo8z lnvgf
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm
8-K
EX-10.1
snb4tq9
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm